Clinical trials underway

Our clinical program is designed to generate high-quality evidence supporting the safety and efficacy of Uroplug for regulatory clearance and clinical adoption.

Study Design

Rigorous, randomized, controlled

Our pivotal clinical study is a prospective, double-blind, randomized, sham-controlled trial designed in consultation with leading clinical investigators and regulatory experts. The study protocol has been developed to support a De Novo or 510(k) submission to the FDA.

The trial evaluates both the therapeutic efficacy and safety of the Uroplug device across a diverse patient population with confirmed diagnosis of the target chronic condition.

Study Design Infographic
Endpoints

Measuring what matters

Primary Endpoint

Symptom Reduction

Statistically significant reduction in [condition-specific validated symptom score] at [X] weeks vs. sham control, measured by [validated instrument].

Secondary Endpoints

Quality of Life & Safety

Patient-reported quality of life improvement (via [PRO instrument]), device safety profile, treatment adherence rates, and durability of response at extended follow-up.

Milestones

Clinical development timeline

Phase — Preclinical

Bench Testing & Preclinical Validation

Completed in-vitro and ex-vivo studies confirming mechanism of action. Biocompatibility and electrical safety testing per ISO 10993 and IEC 60601.

Phase — First-in-Human

Feasibility Study (n=[TBD])

Open-label feasibility study to confirm safety and initial efficacy signals in a small patient cohort. [Planned / In Progress / Complete]

Phase — Pivotal Trial

Randomized Controlled Trial (n=[TBD])

Double-blind, sham-controlled, multi-site pivotal trial. Designed to meet FDA evidentiary requirements for [De Novo / 510(k)] clearance.

Phase — Regulatory

FDA Submission & Market Access

Submission of regulatory dossier. Anticipated timeline for clearance and initial commercial launch. [Target Year TBD]

Early Evidence

Preliminary data highlights

Early-stage data from preclinical and feasibility studies. Full results pending completion of the pivotal trial program.

—%
Symptom Improvement (Placeholder)
0 / 0
SAEs Reported (Placeholder)
—%
Treatment Adherence (Placeholder)

Preliminary data are not indicative of final clinical results. Enrollment status and data availability are subject to change. This section will be updated as data become available.

Regulatory

Pathway to clearance

Uroplug is pursuing a [De Novo / 510(k)] regulatory pathway with the FDA. Our regulatory strategy has been informed by pre-submission meetings and consultation with experienced regulatory counsel.

We are also evaluating CE marking for EU market access and pursuing alignment with international standards (IEC 60601, ISO 13485, ISO 14971).

Regulatory Pathway Diagram

Clinical collaboration opportunities

We welcome inquiries from investigators, clinical sites, and KOLs interested in our research program.

Contact Clinical Team